Stanford researchers in the Mahajan Lab have created a customizable proteomics platform that can identify protein biomarkers to differentiate among ischemic eye diseases and identify novel therapeutic targets to treat them.
Stanford researchers have applied large-scale proteomic platforms to identify biomarkers that can be used to diagnose uveal melanoma and subtype eye tumors according to their gene expression profile (GEP) class or PRAME status.